Martine Rothblatt Sells 4,000 Shares of United Therapeutics (NASDAQ:UTHR) Stock

Key Points

• CEO Martine Rothblatt sold 4,000 shares of United Therapeutics for approximately $1.73 million, reducing her ownership by 96.85% to just 130 shares.
• United Therapeutics reported quarterly earnings of $6.41 per share, missing expectations by $0.39, with revenue at $798.6 million against expectations of $802.1 million.
• Analysts have set a consensus price target of $457.21 for United Therapeutics, with some predicting substantial gains, reflecting strong support from analysts with 10 Buy ratings and 5 Hold ratings.

United Therapeutics Corporation (NASDAQ:UTHR - Get Free Report) CEO Martine Rothblatt sold 4,000 shares of the stock in a transaction dated Thursday, October 16th. The stock was sold at an average price of $431.31, for a total value of $1,725,240.00. Following the sale, the chief executive officer directly owned 130 shares in the company, valued at $56,070.30. This represents a 96.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

United Therapeutics Stock Up 0.1%

Shares of UTHR traded up $0.50 during mid-day trading on Thursday, reaching $432.69. The company had a trading volume of 479,526 shares, compared to its average volume of 594,822. The stock has a market capitalization of $19.52 billion, a P/E ratio of 16.89, a PEG ratio of 4.73 and a beta of 0.66. United Therapeutics Corporation has a 52-week low of $266.98 and a 52-week high of $459.48. The stock has a 50 day moving average of $380.39 and a two-hundred day moving average of $326.20.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its quarterly earnings results on Wednesday, July 30th. The biotechnology company reported $6.41 earnings per share for the quarter, missing the consensus estimate of $6.80 by ($0.39). United Therapeutics had a net margin of 40.36% and a return on equity of 18.73%. The company had revenue of $798.60 million for the quarter, compared to analysts' expectations of $802.13 million. During the same quarter in the prior year, the business posted $5.85 earnings per share. The firm's revenue was up 11.7% compared to the same quarter last year. On average, sell-side analysts expect that United Therapeutics Corporation will post 24.48 earnings per share for the current year.

Analysts Set New Price Targets

A number of equities research analysts have recently commented on UTHR shares. Wells Fargo & Company raised their target price on United Therapeutics from $295.00 to $414.00 and gave the company an "equal weight" rating in a research report on Wednesday, September 3rd. Morgan Stanley lifted their price target on shares of United Therapeutics from $328.00 to $435.00 and gave the company an "equal weight" rating in a research note on Friday, October 10th. HC Wainwright boosted their price target on shares of United Therapeutics from $400.00 to $500.00 and gave the stock a "buy" rating in a report on Friday, September 5th. JPMorgan Chase & Co. decreased their price objective on shares of United Therapeutics from $350.00 to $330.00 and set an "overweight" rating on the stock in a report on Tuesday, July 8th. Finally, Oppenheimer lifted their target price on shares of United Therapeutics from $510.00 to $575.00 and gave the company an "outperform" rating in a research report on Friday, September 5th. Ten equities research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company's stock. Based on data from MarketBeat, United Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $457.21.

Hedge Funds Weigh In On United Therapeutics

A number of hedge funds have recently modified their holdings of UTHR. F m Investments LLC grew its position in United Therapeutics by 1.3% in the 2nd quarter. F m Investments LLC now owns 2,580 shares of the biotechnology company's stock valued at $741,000 after acquiring an additional 33 shares in the last quarter. HB Wealth Management LLC boosted its stake in shares of United Therapeutics by 2.9% in the second quarter. HB Wealth Management LLC now owns 1,235 shares of the biotechnology company's stock valued at $355,000 after purchasing an additional 35 shares during the period. Hohimer Wealth Management LLC boosted its stake in shares of United Therapeutics by 0.3% in the first quarter. Hohimer Wealth Management LLC now owns 12,651 shares of the biotechnology company's stock valued at $3,900,000 after purchasing an additional 37 shares during the period. WealthCollab LLC grew its holdings in shares of United Therapeutics by 55.9% in the second quarter. WealthCollab LLC now owns 106 shares of the biotechnology company's stock valued at $30,000 after purchasing an additional 38 shares in the last quarter. Finally, Park Avenue Securities LLC increased its stake in United Therapeutics by 1.7% during the 2nd quarter. Park Avenue Securities LLC now owns 2,353 shares of the biotechnology company's stock worth $676,000 after buying an additional 39 shares during the period. 94.08% of the stock is currently owned by hedge funds and other institutional investors.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.